Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ymc
    Senior Member
    • Mar 2010
    • 496

    #1

    Question about ONT's Developer Agreement

    Anyone here signed ONT's Developer Agreement?

    I read the fine terms. It seems like anything that built on top of their developer kit will become ONT's intellectual property. Is that true?

    For example, Matt Loose et al's selective sequencing paper:
    The Oxford Nanopore MinION is a portable real time sequencing device which functions by sensing the change in current flow through a nanopore as DNA passes through it. These current values can be streamed in real time from individual nanopores as DNA molecules traverse them. Furthermore, the technology enables individual DNA molecules to be rejected on demand by reversing the voltage across specific channels. In theory, combining these features enables selection of individual DNA molecules for sequencing from a pool, an approach called ‘Read Until’. Here we apply dynamic time warping to match short query current traces to references, demonstrating selection of specific regions of small genomes, individual amplicons from a group of targets, or normalisation of amplicons in a set. This is the first demonstration of direct selection of specific DNA molecules in real time whilst sequencing on any device and enables many novel uses for the MinION.

    uses the ReadUntil capability which is part of the developer kit. Does that mean everything Loose et al developed in that preprint belongs to ONT???
  • gringer
    David Eccles (gringer)
    • May 2011
    • 845

    #2
    I've refused to sign ONT's developer agreement because of the restrictions of use that are claimed by ONT. I much prefer waiting a couple more months and using free software.

    Comment

    • ymc
      Senior Member
      • Mar 2010
      • 496

      #3
      oic. No wonder there were no follow-up to that Matt Loose paper.

      Comment

      • gringer
        David Eccles (gringer)
        • May 2011
        • 845

        #4
        The "read until" is still being developed, but Matt doesn't have much time to specifically work on it, and it's mostly useless now with a sequencing speed of 450 bases per second. Computing matches just takes far too long -- by the time a program has decided whether or not to keep a sequence, a substantial fraction of the reads will have already passed through the pore.

        ONT are currently developing FPGA methods that can make read-until decisions at millisecond timescales, which would bring read-until back into the realm of possibility. A really nice application of read-until is for direct RNA sequencing from total RNA. Imagine being able to decide within 1/10 of a second (or 50bp sequenced) whether or not a sequence is ribosomal RNA, and ejecting anything that fits that profile, freeing up sequencing capacity for non-ribosomal sequences: no more need for ribosomal depletion.

        Comment

        • ymc
          Senior Member
          • Mar 2010
          • 496

          #5
          Interesting, I am also doing something along the line. Nevertheless, I am doing 16S DNA not RNA but presumably should be applicable to RNA. I have a hack specific to 16S that allows me to align R9 data with DTW in O(m*n) time instead of O(m*n*o) where m is 16S length, n is ONT squiggle length and o is number of 16Ses to compare. It sort of works with the R9 data I downloaded in an offline manner. I would like to integrate it with ReadUntil and see how much 16S enrichment I can achieve with a mixed uncultured sample. But the Developer Agreement seems to be not friendly to my situation.

          I think FPGA in the end can solve some problem. But in most cases, it is better for us to have a good algorithm before the FPGA-ization.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
            by SEQadmin2



            CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

            Despite this, “CRISPR helped turn genome editing from a specialized technique into
            ...
            07-31-2026, 11:01 AM
          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 08-06-2026, 07:41 AM
          0 responses
          17 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 08-03-2026, 10:13 AM
          0 responses
          33 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-31-2026, 02:55 AM
          0 responses
          43 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Working...